Village Farms International Inc Dossier - Source-backed chat

Village Farms International Inc

VFFNASDAQ

SectorConsumer Staples

IndustryAgricultural Products

Beta (adjusted)1.21

Intrinsic Value $1.81median of 6 methods · middle span $1-$8based on filings through 30 Jun 2026

Market Price $2.91Price as of 30 Sep 2026

OvervaluedIntrinsic value is 38% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $355.9M

Enterprise Value $322.9M

Shares Outstanding 131.8M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Village Farms International is successfully transitioning from a low-margin agricultural grower to a high-margin, vertically integrated global cannabis pure-play. Following the structural realignment in Q1 2026 to a unified cannabis operating model and the divestment of its legacy U.S. produce business, the company has unlocked significant operational efficiencies. Its core strength lies in its decades of Controlled Environment Agriculture (CEA) expertise, which translates into a highly efficient, low-cost cultivation model. With four consecutive quarters of positive net income, record-breaking international medical exports (particularly in Germany), and a clear runway for growth in the Netherlands, Village Farms represents a highly attractive, fundamentally strong operator trading at a discount compared to speculative peers.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.25

Mean target$4.92

High · most bullish analyst$5.50

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.2520%

Regulatory delays in European markets slow down export growth, and intense price compression in the Canadian recreational market pressures gross margins. Operational delays in the Netherlands Phase II facility or prolonged stagnation in U.S. federal cannabis reform limit near-term expansion, keeping the stock range-bound.

Base CaseCentral scenario

$4.6350%

Village Farms maintains its leading market share in the Canadian dried flower and pre-roll segments while steadily growing its international medical export business. The Netherlands operations scale as planned, contributing to stronger top-line and bottom-line results in the second half of 2026. The company continues to generate positive net income and optimized EBITDA margins under its unified cannabis model.

Bull CaseUpside scenario

$5.5030%

Rapid expansion in Germany and the broader European medical market outpaces expectations, while the Phase II facility in the Netherlands ramps up ahead of schedule to full capacity. Additionally, swift federal regulatory reform in the U.S. allows Village Farms to immediately leverage its massive 5.5 million square feet of Texas greenhouse assets for high-THC cannabis, driving exponential revenue growth and margin expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

World's largest EU-GMP certified cannabis facility in British Columbia, providing a durable low-cost production advantage.
Strong international momentum with medical export sales up 171% YoY in Q1 2026, capturing significant market share in Germany.
Clean balance sheet with low debt relative to Canadian peers and solid cash position following legacy asset sales.
First-mover advantage in the Netherlands' regulated market with production expected to quintuple by the end of 2026.

Key Investment Risks

Volatile regulatory frameworks in international markets, including potential delays in European medical and adult-use rollouts.
Persistent price compression and market saturation within the Canadian recreational cannabis sector.
Execution risks associated with scaling up the Phase II facility in the Netherlands.

Thesis Invalidation Triggers

A significant reversal or multi-year delay in U.S. federal cannabis rescheduling or Texas state-level licensing.
Severe margin compression in the Canadian cannabis segment that drives consolidated Adjusted EBITDA back into negative territory.
Failure to achieve full capacity or projected yields at the Netherlands Phase II facility by the end of 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.